Could HPV (human papilloma virus) vaccine make cervical screening redundant? - Mexico goes first
This article was originally published in Clinica
Will screening for cervical cancer be upstaged by vaccination against the human papilloma virus (HPV), believed to be the leading cause of the disease? Mexico is set to become a test-bed of this possible shift in preventive policy, with potentially major implications for resourcing.
You may also be interested in...
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.